Ultragenyx Pharmaceutical
Ultragenyx Pharmaceutical

Ultragenyx Pharmaceutical

Biotechnology
WebsiteInvestor RelationsSEC
Ultragenyx Pharmaceutical Inc is a USA-based biopharmaceutical company. It identifies, acquires, develops, and commercializes novel products for the treatment of serious rare and ultra-rare diseases, with a focus on serious, debilitating genetic diseases. The company's medicine portfolio includes Crysvita, Dojolvi and Mepsevii. Crysvita is indicated for the treatment of X-linked hypophosphatemia (XLH) in adult and pediatric patients 1 year of age and older. Mepsevii is indicated in pediatric and adult patients for the treatment of Mucopolysaccharidosis VII.

$1.4B

Market Cap • 9/18/2026

2010

(16 years)

Founded

2014

(12 years ago)

IPO

NASDAQ

Listing Exchange

Flag of United States

United States

Country

Valuation

P/B

—

P/S

2

P/EBITDA

—

P/OCF

—

P/FCF

—

P/E

—

BVPS

—

EPS

—

Market Cap

Market Cap

1,4B

EV

1,1B

EV/Revenue

1,6

EV/EBITDA

-2,3

EV/EBIT

-2,2

Payout

Dividend Per Share

0

Dividend Yield

0%

Buyback Yield

-0,3%

Total Yield

-0,3%

Payout

0%

Retained Earnings

-4,8B

Profitability

Gross Margin

83,1%

EBITDA Margin

—

EBIT Margin

—

Net Margin

—

D&A/EBITDA

0%

R&D/Revenue

107,8%

Capex/Revenue

0,6%

Capex/D&A

12,8%

Capex/OCF

-0,9%

SBC/OCF

—

% PPE

18,6%

% Goodwill

3,5%

ROE

932,2%

ROIC

—

Growth

CAGR Revenue 5Y

14,8%

CAGR Op. Income 5Y

9,5%

CAGR Net Income 5Y

10,8%

CAGR EPS 5Y

1,8%

CAGR OCF 5Y

6,8%

Leverage

N.D./EBITDA

0,6

Debt/Equity

0%

Current Ratio

1,7

Quick Ratio

1,4

Interest Coverage

—

Premium

Unlock 100% of the data and have immediate access on more than 6.000 companies with updated information!
  • Unrestricted access
  • Unlimited data history
  • Analysis videos
  • Quarterly highlights
  • Customizable financials table
  • Ranking
  • Discussions

...and much more!

Get Premium